You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,441,274

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,441,274

Title:	In vitro method and kit for prognosis or prediction of response by patients with rheumatoid arthritis to treatment with TNF-.alpha.factor blocking agents
Abstract:	In vitro method and kit for prognosis or prediction of the response of rheumatoid patients to treatment with TNF-.alpha. factor blocking agents, which comprises determining, in a blood sample from said patients, the expression level of at least one of the eight genes selected from the group: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 and TLR5 or combinations thereof and comparing said expression level to the expression values obtained from responsive and non-responsive patients who showed responsiveness to the treatment and those who showed non-responsiveness thereto.
Inventor(s):	Marsal Barril; Sara (Barcelona, ES), Julia Cano; Antonio (Barcelona, ES)
Assignee:	FUNDACIO INSTITUT DE RECERCA DE L\'HOSPITAL UNIVERSITARI VALL D\'HEBRON (Barcelona, ES)
Application Number:	13/120,445
Patent Claims:	1. A method for treating rheumatoid arthritis in a patient, said method comprising: detecting in a sample from the patient the expression level of at least one of the eight genes selected from the group consisting of: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4, and TLR5; and administering a TNF-.alpha. factor blocking agent to the patients which show over-expression of at least one of the genes selected from the group consisting of TLR5, CAMP and SLC2A3; and not administering the TNF-.alpha. factor blocking agent to patients which over-express at least one of the genes selected from the group consisting of MXD4, HLA-DRB3, IL2RB, EAT2, and GNLY, wherein the over-expression is based on the comparison of the expression level of the at least one of the eight genes and the expression values obtained from TNF-.alpha. factor blocking agent responsive and TNF-.alpha. factor blocking agent non-responsive patients. 2. The method, according to claim 1, which comprises the detection of the overall expression level of the group of eight genes consisting of: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 and TLR5. 3. The method, according to claim 1, which comprises the detection of the expression level of any combination of two or more genes of the group of eight genes selected from the group consisting of: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4, and TLR5. 4. The method, according to claim 1, which comprises the detection of the expression level of at least one of the six genes selected from the group consisting of: HLA-DRB3, EAT2, GNLY, CAMP, IL2RB, and TLR5. 5. The method, according to claim 4, which further comprises the detection of the expression level of at least one of the genes: SLC2A3, MXD4, or both SLC2A3 and MXD4. 6. The method, according to claim 1, which comprises the detection of the overall expression level of the group of six genes consisting of: HLA-DRB3, EAT2, GNLY, CAMP, IL2RB and TLR5. 7. The method, according to claim 6, which further comprises the detection of the expression level of at least one of the genes: SLC2A3, MXD4, or both SLC2A3 and MXD4. 8. The method according to claim 1, wherein the rheumatoid arthritis patients (a) fulfill the 1987 ACR (American College of Rheumatology) criteria for rheumatoid arthritis diagnosis and have a DAS28 index >3.2, (b) said patients are tolerant to .ltoreq.20 mg/week methotrexate, (c) said patients are able to receive .ltoreq.10 mg/day prednisolane and treatment with NSAID, wherein the doses of methotrexate, glucocorticoids and NSAID remaining stable during the four weeks prior to treatment with infliximab or adalimumab and said patients have not received any other DMARD during the four weeks prior to the aforesaid treatment with infliximab or adalimumab. 9. The method according to claim 1, wherein the TNF-.alpha. factor blocking agent is selected from infliximab or adalimumab. 10. The method according to claim 1, wherein the expression level is carried out by quantifying mRNA level in a blood sample from the patient.

Details for Patent 9,441,274

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2028-09-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2028-09-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2028-09-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2028-09-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014	⤷ Try a Trial	2028-09-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015	⤷ Try a Trial	2028-09-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.